



Dear Members and contacts,

The BLBG kindly invites you to its next event:

Date:

**Thursday, October 22, 2009
From 4.00 pm till 5.30 pm**

Plant Visit: GlaxoSmithKline Biologicals Singapore



Opened on 9 June 2009, GlaxoSmithKline Biologicals Singapore is GlaxoSmithKline's (GSK) first primary vaccine manufacturing facility and its biggest investment in Asia. The plant costs a total investment of S\$600 million, and underscores GSK's strong commitment to Singapore and the Asia Pacific region. Built on an 85,000 square metre plot of land, the new state-of-the-art facility will include high-tech production buildings, quality control laboratories, a utility plant, a warehouse and other support buildings.

Once operational, the new plant will focus on producing purified bulk polysaccharides and conjugates which are used to manufacture GSK's new pneumococcal conjugate vaccine, meningitis, and other new innovative vaccines. The plant is one of the only two global sites for the production of bulk polysaccharides and conjugates; the other is in Belgium. The first potential commercial lots will be produced in 2011.

Part 1 – Presentation by Vincent Hingot, Site Director and David Callaert, Regional Engineering Director of GlaxoSmithKline Biologicals Singapore

You are invited to a brief introduction to the facility and its operations. There will be opportunities to share experiences and challenges encountered in setting up this Greenfield site.

Part 2 – Site Tour

You are invited on a site tour showcasing part of the critical production facilities as well as an array of new cutting-edge technologies employed at GlaxoSmithKline Biologicals Singapore.

Location: see map attached

GlaxoSmithKline Biologicals
10 Tuas South Avenue 8
Singapore 637421

Please note that it is advisable that participants arrive via taxi instead of driving here individually as visitor parking space on site is limited

Participation fee

BLBG Members	30 SGD
non BLBG Members	40 SGD

Registration

1. Please register with Dominique Soete, before October 15th, by sending back the attached participants list, with the required contact details to:
secretary@blbg.org.sg

Please note that GSK reserves the right to refuse any participants for this event should there seem to be potential conflict of interests.

Made possible by:



2. Send your cheque, addressed to BLAS, to:
Mr. Tan Bing Houw, #01-04, 10 Raeburn Park, 088702 Singapore.
Please mention: *Event: GSK Plant Visit*

Cancellations must be in written and received 48h before the event. No shows will be billed.

Detailed Programme:

- 16:00 – 16:10 Welcome and Site Video
- 16:10 – 16:40 Presentation by Vincent Hingot & David Callaert
- 16:40 – 17:00 Q&A session
- 17:00 – 17:30 Site Tour

Profile of the speakers:

Vincent Hingot is the Site Director for GlaxoSmithKline Biologicals Vaccines Bulk Manufacturing Site in Singapore. He holds a Degree in Biotechnology from Meurice Chimie Institute and Bachelor of Chemical Engineering from University of Bruxelles (ULB).

Since joining GSK Biologicals in 1991, he has been responsible for several projects in vaccine manufacturing sites throughout the GSK Global Industrial Operations network. In 2000, he was involved in the concept, design, construction and validation of a new bulk manufacturing facility in Wavre (Belgium). He was responsible for process transfer and the start-up of this worldwide supply bulk facility. In 2003, he was in charge of conceptual, basic and detailed design of a New Flu manufacturing facility in Dresden (Germany) and Project Manager for revamping of DTPa and animal house facilities in Godollo (Hungary). Following which, he was responsible for GSK's cervical cancer vaccine large scale cell culture process scale-up including upstream and downstream processes in 2005 before assuming his role in Singapore.

Prior to GSK Biologicals, he worked some years in the petrochemical and electronics industry.

David Callaert is the Regional Engineering Director for GlaxoSmithKline Biologicals Vaccines Bulk Manufacturing Site in Singapore. He holds a Master in Chemical Engineering from Catholic University of Leuven (KUL), Belgium.

David has 13 years of experience in the Pharmaceutical industry, of which nine years were based in Singapore. He joined GlaxoSmithKline Biologicals Singapore in 2006 as the Project Director for the Greenfield vaccine facility. In 2007, he assumed his current role as Regional Engineering Director, in charge of a regional portfolio of large and medium sized projects delivery on top of his responsibility as Project Director.

For more information

Dominique Soete
Executive Director BLBG
P/a: 10, Raeburn Park #01-04
Singapore 088702
Phone: +65 93223086
e-mail: dominique.soete@blbg.org.sg
Website: www.blbg.org.sg